Cardiff Oncology, Inc. (CRDF) › Cash & EquivalentsCardiff Oncology, Inc. (CRDF) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2010-12-31: $58.7K2011-12-31: $700.4K2012-12-31: $10.82M2013-12-31: $25.84M2014-12-31: $27.29M2015-12-31: $67.49M2016-12-31: $13.92M2017-12-31: $8.23M2018-12-31: $11.45M2019-12-31: $10.20M2020-12-31: $130.98M2021-12-31: $11.94M2022-12-31: $16.35M2023-12-31: $21.66M2024-12-31: $51.47M2025-12-31: $17.47M$17.47M2010-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$17.47M-66.1%2026-02-24Balance as of period end2024-12-31$51.47M+137.7%2026-02-24Balance as of period end2023-12-31$21.66M+32.5%2025-02-27Balance as of period end2022-12-31$16.35M+36.9%2024-02-29Balance as of period end2021-12-31$11.94M-90.9%2023-03-02Balance as of period end2020-12-31$130.98M+1184.7%2022-02-24Balance as of period end2019-12-31$10.20M-11.0%2021-02-25Balance as of period end2018-12-31$11.45M+39.2%2020-02-27Balance as of period end2017-12-31$8.23M-40.9%2019-03-06Balance as of period end2016-12-31$13.92M-79.4%2019-03-06Balance as of period end2015-12-31$67.49M+147.3%2018-02-26Balance as of period end2014-12-31$27.29M+5.6%2017-03-15Balance as of period end2013-12-31$25.84M+138.8%2017-03-15Balance as of period end2012-12-31$10.82M+1444.9%2016-03-10Balance as of period end2011-12-31$700.4K+1093.1%2015-03-12Balance as of period end2010-12-31$58.7K—2014-03-17Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)